RxSight, Inc. Common Stock
RXSTRxSight, Inc. is a medical device company specializing in the development and commercialization of innovative ophthalmic products. Its primary focus is on improving outcomes for patients undergoing cataract surgery through its flagship product, the Light Adjustable Lens (LAL), which allows customization and post-operative adjustments to optimize visual results. The companyโs technology aims to enhance the precision and flexibility of cataract treatment.
Company News
RxSight, Inc. announced preliminary 2025 full-year revenue of $134.5 million, exceeding guidance, driven by 109,615 Light Adjustable Lens procedures (12% increase YoY) and expansion of its installed base to 1,134 Light Delivery Devices. The company also appointed Mark Wilterding as Chief Financial Officer, bringing 25+ years of medtech financial ...
DJS Law Group is investigating RxSight, Inc. for potential securities law violations after the company reported significant financial declines, including reduced sales of Light Delivery Devices and lowered annual financial guidance.
Faruqi & Faruqi is investigating potential securities law violations by RxSight after the company reported significant sales declines and lowered financial guidance, causing its stock price to drop 37.8%.
Rosen Law Firm reminds RxSight investors who purchased securities between May 7, 2024 and July 8, 2025 about an upcoming September 22, 2025 deadline for a securities class action lawsuit, alleging the company misrepresented its growth potential and market performance.
Rosen Law Firm is alerting RxSight investors about a September 22, 2025 deadline for a securities class action lawsuit, alleging the company made false statements about customer adoption and growth metrics.
